Compare IMMR & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMMR | MDXH |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.7M | 183.4M |
| IPO Year | 1999 | 2021 |
| Metric | IMMR | MDXH |
|---|---|---|
| Price | $6.10 | $3.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $12.25 | $7.67 |
| AVG Volume (30 Days) | ★ 316.3K | 107.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.12 | N/A |
| Revenue | ★ $35,013,000.00 | N/A |
| Revenue This Year | $168.87 | $23.34 |
| Revenue Next Year | $109.72 | $22.98 |
| P/E Ratio | $2.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.65 | $1.35 |
| 52 Week High | $8.15 | $5.33 |
| Indicator | IMMR | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 43.71 | 41.09 |
| Support Level | $5.71 | $3.05 |
| Resistance Level | $7.03 | $3.78 |
| Average True Range (ATR) | 0.21 | 0.18 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 56.88 | 13.21 |
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.